BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Radu P, Dufour JF. Changing TACTICS in intermediate HCC: TACE plus sorafenib. Gut 2020;69:1374-6. [PMID: 32169908 DOI: 10.1136/gutjnl-2020-320692] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Cao S, Zhu S, Yin W, Xu H, Wu J, Wang Q. Relevance of EGFR Between Serum VEGF and MMP-9 in Primary Hepatocellular Carcinoma Patients with Transarterial Chemoembolization. Onco Targets Ther 2020;13:9407-17. [PMID: 33061427 DOI: 10.2147/OTT.S257271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Yang F, Yang J, Xiang W, Zhong BY, Li WC, Shen J, Zhang S, Yin Y, Sun HP, Wang WS, Zhu XL. Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma. Front Oncol 2021;11:657512. [PMID: 35096555 DOI: 10.3389/fonc.2021.657512] [Reference Citation Analysis]
3 Yang X, Feng Y, Liu Y, Ye X, Ji X, Sun L, Gao F, Zhang Q, Li Y, Zhu B, Wang X. Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway. Phytomedicine 2021;87:153575. [PMID: 33984593 DOI: 10.1016/j.phymed.2021.153575] [Reference Citation Analysis]